BRMS1: A Gene Involved in Cancer Development and Progression (G25855)

Target Name: BRMS1

NCBI ID: G25855

BRMS1

Other Name(s): BRMS1 variant 1 | Breast cancer metastasis-suppressor 1 (isoform 1) | BRMS1 transcriptional repressor and anoikis regulator, transcript variant 1 | Breast cancer metastasis-suppressor 1 | BRMS1 transcriptional repressor and anoikis regulator | BRMS1_HUMAN | breast cancer metastasis suppressor 1

BRMS1: A Gene Involved in Cancer Development and Progression

BRMS1 (Bcr/Abl-regulated murine sarcoma viral homolog 1) is a gene that encodes a protein known as Bcr/Abl-regulated murine sarcoma viral homolog 1. This gene is located on chromosome 18 and encodes a protein that is involved in the development and progression of various types of cancer.

BRMS1 is a tumor suppressor gene that plays a critical role in the development and progression of cancer. It is known to be involved in the regulation of the Bcr/Abl signaling pathway, which is a critical pathway that is involved in the development and progression of many types of cancer.

BRMS1 is also known to be involved in the regulation of cell division, and it is thought to play a role in the regulation of the number of cells that are produced by a cell. This is important for the growth and development of cancer, as an imbalance in cell division can lead to the formation of cancerous tumors.

BRMS1 is also known to be involved in the regulation of gene expression, and it is thought to play a role in the regulation of the expression of genes that are involved in cell growth and differentiation. This is important for the development and progression of cancer, as the regulation of gene expression is critical for the development and growth of cancer cells.

BRMS1 is also known to be involved in the regulation of cellular signaling pathways, and it is thought to play a role in the regulation of the signaling pathways that are involved in the development and progression of cancer. This is important for the development and progression of cancer, as the regulation of cellular signaling pathways is critical for the growth and development of cancer cells.

BRMS1 is also known to be involved in the regulation of inflammation, and it is thought to play a role in the regulation of the inflammatory response that is triggered by the development of cancer. This is important for the development and progression of cancer, as the regulation of inflammation is critical for the growth and development of cancer cells.

In conclusion, BRMS1 is a gene that is involved in the development and progression of cancer. It is a tumor suppressor gene that plays a critical role in the regulation of the Bcr/Abl signaling pathway, cell division, gene expression, cellular signaling pathways, and inflammation. As a drug target or biomarker, BRMS1 may be a useful target for the development of new cancer therapies.

Protein Name: BRMS1 Transcriptional Repressor And Anoikis Regulator

Functions: Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma

The "BRMS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BRMS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets